Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
종목 코드 AMRN
회사 이름Amarin Corporation PLC
상장일Apr 01, 1993
CEOMr. Aaron D. Berg
직원 수275
유형Depository Receipt
회계 연도 종료Apr 01
주소WeWork One Central Plaza Dame Street
도시DUBLIN
증권 거래소NASDAQ Capital Market Consolidated
국가Ireland
우편 번호D02 K7K5
전화35316699020
웹사이트https://amarincorp.com/
종목 코드 AMRN
상장일Apr 01, 1993
CEOMr. Aaron D. Berg
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음